A carregar...
In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1(+) BCP-ALL
Despite the addition of tyrosine kinase inhibitors (TKIs) to the treatment of patients with BCR-ABL1(+) B-cell precursor acute lymphoblastic leukemia (BCR-ABL1(+) BCP-ALL), relapse both with and without BCR-ABL1 mutations is a persistent clinical problem. To identify BCR-ABL1–independent genetic med...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5998924/ https://ncbi.nlm.nih.gov/pubmed/29853524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015610 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|